Isabel Jaco
Senior Principal Scientist & Group leader - Radioligand Therapy Drug Discovery Novartis AG
Seminars
Tuesday 11th November 2025
Examining the Success Story of Pluvicto: Strategies, Approaches & Next Steps
8:30 am
Radiopharmaceuticals are on the rise worldwide. Join key players to explore how Europe is driving progress in this exciting field – and what it means for the future of cancer care around the world.
- Demonstrating significant progression-free survival benefits for mCRPC patients treated with Pluvicto
- Enhancing treatment outcomes when combining Pluvicto with enzalutamide in mCRPC therapy
- Increasing real-world use of Pluvicto in both academic and community settings to improve patient accessibility
